Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent

摘要

A combination comprising: (a) a therapeutically-effective amount of at least one compound which is: or a pharmaceutically acceptable salt thereof; (b) a hormone ablation agent; and (c) a therapeutically-effective amount of an additional therapeutic agent selected from the group consisting of an anti-androgen agent, docetaxel, and prednisone; for use in the treatment of a refractory prostate cancer in a subject in need thereof. In another aspect, the same combination is used to treat and androgen-dependent disorder. Preferably, the hormone ablation agent is selected from the group consisting of deslorelin, leuprolide, goserelin, and triptorelin. Preferred anti-androgen agents are selected from the group consisting of bicalutamide, flutamide, spironolactone, cyproterone acetate, finasteride, dutasteride, and nilutamide. More, preferably, the anti-androgen agent is bicalutamide or flutamide and the hormone ablation agent is leuprolide. The compound of formula I is also known as galeterone.